We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Genotoxic Genes in Certain Gut Bacteria Linked to Chronic Bowel Inflammation and Colon Cancer

By LabMedica International staff writers
Posted on 29 Aug 2012
Certain strains of gut bacteria - Escherichia coli bearing the polyketide synthase (pks) cluster of genotoxic genes – have been linked to chronic inflammatory bowel diseases such as Crohn's disease and ulcerative colitis and to the development of colorectal cancer (CRC).

Polyketide synthases are a family of multidomain enzymes or enzyme complexes that produce polyketides, a large class of secondary metabolites in bacteria, fungi, plants, and a few animal lineages. More...
Polyketide synthase products include lipids with antibiotic, antifungal, antitumor, and predator-defense properties. They are an important source of naturally occurring small molecules used for chemotherapy. For example, many of the commonly used antibiotics, such as tetracyclin, and macrolides are produced by polyketide synthases. Other industrially important polyketides are rapamycin (immunosuppressant), erythromycin (antibiotic), lovastatin (anticholesterol drug), and epothilone B (anticancer drug).

Investigators at the University of Liverpool (United Kingdom) and colleagues in the USA and Canada used high-throughput sequencing to reveal that inflammation modified gut microbial composition in colitis-susceptible interleukin-10–deficient (Il10−/−) mice. Monocolonization with the commensal Escherichia coli strain NC101 promoted invasive carcinoma in azoxymethane (AOM)–treated Il10−/− mice. Furthermore, mucosa-associated pks+ E. coli were found in a significantly high percentage of human inflammatory bowel disease and CRC patients.

Other results published in the August 16, 2012, online edition of the journal Science revealed that deletion of the polyketide synthase (pks) genotoxic island from E. coli NC101 decreased tumor multiplicity and invasion in AOM/Il10−/− mice, without altering intestinal inflammation.

Contributing author Dr. Jonathan Rhodes, professor of medicine at the University of Liverpool, said, "The fact that the pks-positive E. coli seemed to promote colon cancer in mice without causing increased inflammation led us to investigate its possible role in human colon cancer. The marked increase in the presence of these bacteria in the colon, not only in patients with inflammatory bowel disease, but also in patients with colon cancer who do not have inflammatory bowel disease, suggests that damage caused to DNA, as a result of the toxin that the pks genes produce, may promote the development of colon cancer."

Related Links:

University of Liverpool



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.